Pharma Show

The Top 3 Preclinical Considerations in the Discovery and Development of Novel Oncology Therapeutics

Hosted By :  Andrea Charles
November 6, 2012
Rate this Podcast: (Be the First!)

Tags : predictive toxicology | preclinical considerations | computational biology | clinical drug development | novel oncology therapeutics | Ken Olivier | Merrimack Pharmaceuticals

About this Podcast...

In this interview Kenneth J. Olivier Jr., PhD, Director of Toxicology at Merrimack Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about what trends he is witnessing in the improvement of safety assessments, his top 3 preclinical considerations in the discovery and development of novel oncology therapeutics and the implications and future considerations for use of computational biology in clinical drug development.

Have Your Say
Rate this feature and give us your feedback in the comments section below

Rate this Podcast: (Be the First!)



To continue viewing this content please fill out the form below and become an IQ member.
Or if you're already a Pharma IQ member, sign in to continue.

First Name*
Last Name*
Job Title*
Company*
Country
State
E-mail*
Username*
Password*
Confirm Password*

By clicking Submit, you accept our User Agreement, Privacy Policy, and Cookie Policy.




comments powered by Disqus


Advertise With Us

Join the Pharmas IQ Community